“Our aim is to develop and commercialize molecular tools for life science research and molecular diagnostics. With a strong and dedicated R&D team, and with close links to the founding laboratory at Uppsala University, we now focus on in-situ detection methods, and blood tests based on cell-free DNA (cfDNA) for diagnostic screening purposes.” – Peter Åsberg CEO, Olink Bioscience.
Intellectual Properties and Licensing opportunities
Olink Bioscience is committed to realizing the exciting potential of the Company’s extensive and growing IP portfolio. Our primary goal is to develop high-end products and/or tools meeting unmet clinical and research needs with a significant market potential. Olink Bioscience is also open to out-license some of technology IP, please contact CEO in case of interest.
Selected Science & Technology examples
“The greatest advantage of the proxHCR method is its independence from enzymatic steps, while retaining the specificity of PLA. This reduces costs of the assay considerably, making the method better suited for high-throughput screening of protein interactions. ” Björn Koos (https://www.ncbi.nlm.nih.gov/pubmed/26065580)
Can we help you?
Let us know how best to contact you below (note: email or number only - input format is verified)